Avacta Group (LON:AVCT)‘s stock had its “corporate” rating reissued by equities research analysts at FinnCap in a research report issued to clients and investors on Monday. They presently have a GBX 200 ($2.71) price target on the biotechnology company’s stock. FinnCap’s price target points to a potential upside of 187.40% from the company’s current price.
Shares of Avacta Group (LON:AVCT) traded up GBX 4.09 ($0.06) on Monday, reaching GBX 69.59 ($0.94). The company had a trading volume of 34,466 shares, compared to its average volume of 6,263. The company has a market capitalization of $36.99 and a P/E ratio of -773.22. Avacta Group has a 12 month low of GBX 60 ($0.81) and a 12 month high of GBX 98 ($1.33).
About Avacta Group
Avacta Group plc is a biotechnology company. Avacta’s focus is on its proprietary Affimer technology which is an engineered alternative to antibodies that has application in Life Sciences for diagnostics, therapeutics and general research and development. Affimer technology has been designed to address performance limitations of antibodies.
Receive News & Ratings for Avacta Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avacta Group and related companies with MarketBeat.com's FREE daily email newsletter.